Optimal Pharmacotherapy for Transplant-Ineligible Multiple Myeloma


Project Status:
Open for Stakeholder Feedback
Project Line:
Reimbursement Review
Project Sub Line:
Therapeutic Review
Project Number:
TR0014-000 - OP0547-000
Effective finish date:

Multiple myeloma (MM) is a hematological cancer that mainly affects individuals older than 65 years of age. Though MM remains incurable, several life-prolonging pharmacotherapies for the treatment of newly diagnosed, relapsed, or refractory MM were reviewed by CADTH and are available or being considered for public reimbursement in Canada. However, at this time, the optimal sequence of therapies is unclear. CADTH is preparing a Therapeutic Review considering multiple MM drugs and treatment steps in order to help decision-makers develop appropriate pharmaceutical funding policies.

Projects listed as “in progress” are at various stages and points of completion. These products have different processes and timelines; therefore, the timing of posting of the final reports varies and expected completion dates may change. Find out more about Projects in Progress.

The “Projects in Progress” page on the CADTH website is updated on a seven- to eight-day cycle. Please be advised that there may be overlap between when a new report is posted online and when the section is updated. View our current Projects in Progress.

Call for feedback
Call for feedback:
Feedback Due By
Feedback Due By:
Consultation document
Consultation document: Draft Clinical Report
Product Line
Product Line: Reimbursement Review
Project Number
Project Number: TR0014-000 - OP0547-000